March 24th 2017
Whereas the androgen receptor (AR) is a common target in prostate cancer, emerging findings are showing a potential role for targeting AR in breast cancer, as well.
March 13th 2017
Michael F. Press, MD, PhD, discusses issues with the ASCO-CAP guidelines on assessment of HER2 amplification by fluorescence in situ hybridization testing.
February 20th 2017
Dr. Elizabeth Swisher discusses biomarkers for PARP inhibitors and the evolving role of these agents in ovarian cancer.
February 17th 2017
Results of a phase I expansion study demonstrated a manageable safety profile and clinical activity with mirvetuximab soravtansine in the treatment of patients with platinum-resistant ovarian cancer.
February 13th 2017
Rovalpituzumab tesirine demonstrated encouraging single-agent antitumor activity with a manageable safety profile in the treatment of patients with recurrent small cell lung cancer.
February 10th 2017
Intentional weight loss in postmenopausal women has been found to be associated with a lower endometrial cancer risk, particularly among those with obesity, according to the results of a recent study published in the Journal of Clinical Oncology.
February 8th 2017
Anne Rositch, PhD, discusses important takeaways from her study on hysterectomy-corrected mortality rates in cervical cancer and the significance of cervical cancer screening.
February 6th 2017
The addition of hormonal therapy to radiation treatment following surgery significantly improved survival in patients with recurrent prostate cancer, according to the results of a study published in The New England Journal of Medicine.
January 28th 2017
Diagnostic laparoscopy reduced the number of futile laparotomies in patients with suspected advanced-stage ovarian cancer, according to the results of a recent study.
January 27th 2017
A prostate-specific antigen nadir greater than 0.5 ng/mL following radiation and androgen deprivation therapy seems to identify men prior to PSA failure who are at high-risk for death, and would thus require more aggressive treatment for their prostate cancer.